Physician profile
Zeyar Thet
NPI 1356429922
$27,867.44
in general payments reported to CMS, 2019-2025
29 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $410 · 2021: $706 · 2022: $3,222 · 2023: $1,785 · 2024: $5,218 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,516 · Consulting Fee: $4,741 · Travel and Lodging: $273 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,035.00 |
| Food and Beverage | $5,516.25 |
| Consulting Fee | $4,740.50 |
| Travel and Lodging | $273.39 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13,924.99 | 2019-2025 | Descovy, Yeztugo, Epclusa |
| Shionogi INC | $5,087.30 | 2021-2025 | S-217622, Fetroja |
| Viiv Healthcare Company | $3,142.38 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $1,908.17 | 2019-2024 | Mavyret, Dalvance, Avycaz |
| Janssen Biotech, INC. | $639.39 | 2019-2023 | Symtuza |
| Insmed, INC. | $466.39 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $348.22 | 2019-2024 | Xarelto |
| Janssen Products, LP | $299.91 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.62 | 2022-2025 | Ofev, Jardiance |
| Medtronic, INC. | $218.51 | 2022 | |
| Emd Serono, INC. | $200.31 | 2019-2024 | Serostim |
| Melinta Therapeutics, LLC | $190.96 | 2019-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Merck Sharp & Dohme LLC | $188.57 | 2022-2025 | Capvaxive |
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Exact Sciences Corporation | $124.62 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $106.35 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $102.51 | 2023-2024 | Uzedy |
| Janssen Scientific Affairs, LLC | $93.15 | 2019-2023 | Symtuza, Prezista |
| Shire North American Group INC | $92.79 | 2019 | |
| Pfizer INC. | $83.22 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.78 | 2019-2022 | |
| Theratechnologies INC. | $39.82 | 2025 | Trogarzo, Egrifta |
| Dynavax Technologies Corporation | $29.77 | 2023 | Heplisav-B |
| Astellas Pharma US INC | $28.99 | 2019 | |
| Renalytix Ai, INC. | $24.34 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bioxcel Therapeutics, INC. | $23.21 | 2023 | Igalmi |
| Alkermes, INC. | $22.60 | 2024 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $19.74 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeyar Thet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.